{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.11074","value":"0.4017"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Dosing interval was 24 hours for QD dosing regimen. Aetau% was calculated as 100\\*Ae24/dose, where Ae24 was the cumulative amount of drug recovered unchanged in urine up to 24 hours post-dose.","dispersionType":"Standard Deviation","groups":[{"description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG000","title":"100 mg QD (Phase 1)"}],"paramType":"MEAN","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. As planned, this parameter was only analyzed for 100 mg QD group. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"0-4 hours, 4-12 hours and 12-24 hours post-dose on Cycle 1 Day 15","title":"Percent of PF-06463922 Recovered Unchanged in Urine up to Dosing Interval (AEtau%) (Phase 1)","type":"SECONDARY","unitOfMeasure":"Percentage of recovered PF-06463922"}